Does volume change of the spleen correlate with the therapy response in uveal melanoma patients with liver metastases undergoing hepatic artery infusion chemotherapy?

Steinberg-Vorhoff, Hannah Luisa; Drews, Marcel; Siveke, Jens; Li, Yan; Schaarschmidt, Benedikt Michael; Forsting, Michael; Salhöfer, Luca; Zensen, Sebastian; Richly, Heike; Landeghem, Natalie van; Haubold, Johannes; Holtkamp, Mathias; Opitz, Marcel

doi:10.2478/raon-2025-0047

Items
Marc 21

001			304599
005			20250919115032.0
024	7	_	\|a 10.2478/raon-2025-0047 \|2 doi
024	7	_	\|a pmid:40959926 \|2 pmid
024	7	_	\|a pmc:PMC12441889 \|2 pmc
024	7	_	\|a 0485-893X \|2 ISSN
024	7	_	\|a 1318-2099 \|2 ISSN
024	7	_	\|a 1581-3207 \|2 ISSN
037	_	_	\|a DKFZ-2025-01918
041	_	_	\|a English
082	_	_	\|a 610
100	1	_	\|a Steinberg-Vorhoff, Hannah Luisa \|b 0
245	_	_	\|a Does volume change of the spleen correlate with the therapy response in uveal melanoma patients with liver metastases undergoing hepatic artery infusion chemotherapy?
260	_	_	\|a Warsaw \|c 2025 \|b Sciendo
336	7	_	\|a article \|2 DRIVER
336	7	_	\|a Output Types/Journal article \|2 DataCite
336	7	_	\|a Journal Article \|b journal \|m journal \|0 PUB:(DE-HGF)16 \|s 1758201490_22605 \|2 PUB:(DE-HGF)
336	7	_	\|a ARTICLE \|2 BibTeX
336	7	_	\|a JOURNAL_ARTICLE \|2 ORCID
336	7	_	\|a Journal Article \|0 0 \|2 EndNote
520	_	_	\|a Uveal melanoma (UM) patients with liver metastases often undergo hepatic artery infusion therapy (HAIC). Due to diffuse metastatic spread in the liver, patients often develop hepatomegaly and secondary, portal hypertension which may lead to splenomegaly. This study aimed to compare spleen volumetry and the change of spleen volume (SV) for the evaluation of HAIC treatment response.In this study, 179 UM patients (mean age 64.8 ± 11.0y, 53% female) with liver metastases undergoing HAIC were included. Treatment response was analyzed by RECIST 1.1 and SV on CT imaging before and after first HAIC. The correlation of change in spleen and liver volume was analyzed with Spearman test. Overall survival (OS) was calculated as the time from the first HAIC to patient death using Kaplan-Meier test and multivariate analysis was performed for RECIST 1.1 and SV.In the study population, OS was 13.8 months (95% CI 10.6-14.7 months). Change in SV before and after first HAIC was +4% (interquartile range [IQR] -4.0%-12.0%, p = 0.49) and showed a weak correlation with OS (r = -0.11, p = 0.18). UM patients with progressive disease (PD) according to RECIST 1.1 showed an increase in SV compared to patients with stable disease (SD) (p = 0.04). Compared to RECIST 1.1, SV was not significant prognostic factor that can identify a change in OS.In uveal melanoma patients with liver metastases undergoing HAIC, neither the change of SV nor splenomegaly could be identified as prognostic factors for OS.
536	_	_	\|a 899 - ohne Topic (POF4-899) \|0 G:(DE-HGF)POF4-899 \|c POF4-899 \|f POF IV \|x 0
588	_	_	\|a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650	_	7	\|a hepatic artery infusion chemotherapy \|2 Other
650	_	7	\|a liver metastases \|2 Other
650	_	7	\|a spleen size \|2 Other
650	_	7	\|a survival \|2 Other
650	_	7	\|a uveal melanoma \|2 Other
650	_	2	\|a Humans \|2 MeSH
650	_	2	\|a Uveal Neoplasms: pathology \|2 MeSH
650	_	2	\|a Uveal Neoplasms: drug therapy \|2 MeSH
650	_	2	\|a Female \|2 MeSH
650	_	2	\|a Melanoma: drug therapy \|2 MeSH
650	_	2	\|a Melanoma: pathology \|2 MeSH
650	_	2	\|a Melanoma: secondary \|2 MeSH
650	_	2	\|a Melanoma: diagnostic imaging \|2 MeSH
650	_	2	\|a Middle Aged \|2 MeSH
650	_	2	\|a Male \|2 MeSH
650	_	2	\|a Liver Neoplasms: secondary \|2 MeSH
650	_	2	\|a Liver Neoplasms: drug therapy \|2 MeSH
650	_	2	\|a Liver Neoplasms: diagnostic imaging \|2 MeSH
650	_	2	\|a Infusions, Intra-Arterial \|2 MeSH
650	_	2	\|a Spleen: pathology \|2 MeSH
650	_	2	\|a Spleen: diagnostic imaging \|2 MeSH
650	_	2	\|a Uveal Melanoma \|2 MeSH
650	_	2	\|a Aged \|2 MeSH
650	_	2	\|a Hepatic Artery \|2 MeSH
650	_	2	\|a Organ Size \|2 MeSH
650	_	2	\|a Retrospective Studies \|2 MeSH
650	_	2	\|a Tomography, X-Ray Computed \|2 MeSH
650	_	2	\|a Treatment Outcome \|2 MeSH
700	1	_	\|a Drews, Marcel \|b 1
700	1	_	\|a Opitz, Marcel \|b 2
700	1	_	\|a Landeghem, Natalie van \|b 3
700	1	_	\|a Salhöfer, Luca \|b 4
700	1	_	\|a Holtkamp, Mathias \|b 5
700	1	_	\|a Li, Yan \|b 6
700	1	_	\|a Haubold, Johannes \|b 7
700	1	_	\|a Siveke, Jens \|0 P:(DE-He78)026e0a55b968f360a3c349689ce8a99c \|b 8 \|u dkfz
700	1	_	\|a Richly, Heike \|b 9
700	1	_	\|a Forsting, Michael \|b 10
700	1	_	\|a Schaarschmidt, Benedikt Michael \|b 11
700	1	_	\|a Zensen, Sebastian \|b 12
773	_	_	\|a 10.2478/raon-2025-0047 \|g Vol. 59, no. 3, p. 383 - 390 \|0 PERI:(DE-600)2134813-3 \|n 3 \|p 383 - 390 \|t Radiology and oncology \|v 59 \|y 2025 \|x 1318-2099
909	C	O	\|o oai:inrepo02.dkfz.de:304599 \|p VDB
910	1	_	\|a Deutsches Krebsforschungszentrum \|0 I:(DE-588b)2036810-0 \|k DKFZ \|b 8 \|6 P:(DE-He78)026e0a55b968f360a3c349689ce8a99c
913	1	_	\|a DE-HGF \|b Programmungebundene Forschung \|l ohne Programm \|1 G:(DE-HGF)POF4-890 \|0 G:(DE-HGF)POF4-899 \|3 G:(DE-HGF)POF4 \|2 G:(DE-HGF)POF4-800 \|4 G:(DE-HGF)POF \|v ohne Topic \|x 0
914	1	_	\|y 2025
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0200 \|2 StatID \|b SCOPUS \|d 2024-12-17
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0300 \|2 StatID \|b Medline \|d 2024-12-17
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0501 \|2 StatID \|b DOAJ Seal \|d 2023-04-12T15:07:06Z
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0500 \|2 StatID \|b DOAJ \|d 2023-04-12T15:07:06Z
915	_	_	\|a Peer Review \|0 StatID:(DE-HGF)0030 \|2 StatID \|b DOAJ : Peer review \|d 2023-04-12T15:07:06Z
915	_	_	\|a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version) \|0 LIC:(DE-HGF)CCBYNCNDNV \|2 V:(DE-HGF) \|b DOAJ \|d 2023-04-12T15:07:06Z
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0199 \|2 StatID \|b Clarivate Analytics Master Journal List \|d 2024-12-17
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0160 \|2 StatID \|b Essential Science Indicators \|d 2024-12-17
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)1110 \|2 StatID \|b Current Contents - Clinical Medicine \|d 2024-12-17
915	_	_	\|a WoS \|0 StatID:(DE-HGF)0113 \|2 StatID \|b Science Citation Index Expanded \|d 2024-12-17
915	_	_	\|a DBCoverage \|0 StatID:(DE-HGF)0150 \|2 StatID \|b Web of Science Core Collection \|d 2024-12-17
915	_	_	\|a JCR \|0 StatID:(DE-HGF)0100 \|2 StatID \|b RADIOL ONCOL : 2022 \|d 2024-12-17
915	_	_	\|a IF < 5 \|0 StatID:(DE-HGF)9900 \|2 StatID \|d 2024-12-17
915	_	_	\|a Article Processing Charges \|0 StatID:(DE-HGF)0561 \|2 StatID \|d 2024-12-17
915	_	_	\|a Fees \|0 StatID:(DE-HGF)0700 \|2 StatID \|d 2024-12-17
920	1	_	\|0 I:(DE-He78)ED01-20160331 \|k ED01 \|l DKTK Koordinierungsstelle Essen/Düsseldorf \|x 0
980	_	_	\|a journal
980	_	_	\|a VDB
980	_	_	\|a I:(DE-He78)ED01-20160331
980	_	_	\|a UNRESTRICTED

Library	Collection	CLSMajor	CLSMinor	Language	Author

Marc 21

guest :: login DKFZ
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help